Skip to main content
OpenTrials
Completed

NCT Number: NCT06125912

A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging

This study will evaluate the efficacy of the DIME TBT Cream in improving the appearance and hydration of aged skin in comparison to a retinol cream. This study will last for 60 days. The study will be conducted as a single-arm trial in which all participants will use both the test product and the positive control product (0.1% Retinol Clinical Trial Lotion). Participants will be required to undertake questionnaires at Baseline, Day 30, and Day 60. Photos will be taken at Baseline, Day 30, and Day 60, and expert skin grading will take place at Baseline and Day 60.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Aging

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Santa Monica, California, 90404, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Females aged 18-65. Have one or more of the following: visible fine lines and wrinkles, dry skin, reduced skin elasticity, or generally unhealthy skin.

Must be willing to use two different skincare products, one on each side of their face for the duration of the trial.

Have a smartphone or camera to take before-and-after selfies.

Exclusion criteria

Anyone not in good health. Anyone who has any chronic health conditions such as oncological or psychiatric disorders.

Anyone who has any known serious allergic reactions that require the use of an Epi-Pen.

Anyone who is pregnant, breastfeeding, or wanting to become pregnant over the next three months.

Anyone who cannot/ will not commit to the study protocol. Anyone with a history of substance abuse.

Treatment and study plan

Dime Beauty TBT Cream

Other

Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.

Positive Control

Other

Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.

Other names: 0.1% Retinol Clinical Trial Lotion

Primary outcomes

  1. Change in the appearance of fine lines and wrinkles on the face. [Baseline to Day 60]

    Time frame: 60 days

    Photos of the participants' face before and after the intervention will be evaluated for a change in this parameter by a board-certified dermatologist.

  2. Change in participants' perception of the appearance of fine lines and wrinkles on the face. [Baseline to Day 60]

    Time frame: 60 days

    Measured via participant-reported questionnaires. Questionnaires will be designed using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").

  3. Change in skin elasticity. [Baseline to Day 60]

    Time frame: 60 days

    Measured via participant-reported questionnaires. Questionnaires will be designed using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").

  4. Changes in signs of skin aging. [Baseline to Day 60]

    Time frame: 60 days

    Photos of the participants' face before and after the intervention will be evaluated for a change in this parameter by a board-certified dermatologist.

  5. Changes in participants' perception of signs of skin aging. [Baseline to Day 60]

    Time frame: 60 days

    Measured via participant-reported questionnaires. Questionnaires will be designed using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").

  6. Changes in participants' perception of facial skin hydration. [Baseline to Day 60]

    Time frame: 60 days

    Measured via participant-reported questionnaires. Questionnaires will be designed using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").

  7. Changes in facial skin hydration. [Baseline to Day 60]

    Time frame: 60 days

    Photos of the participants' face before and after the intervention will be evaluated for a change in this parameter by a board-certified dermatologist.

Secondary outcomes

  1. Comparison of the visual changes in the signs of skin aging as a result of using the test product compared to the control product. [Baseline to Day 60]

    Time frame: 60 days

    Photos of the participants' face before and after the intervention will be evaluated for a change in this parameter by a board-certified dermatologist. The left side of the face and the right side of the face will be compared.

  2. Comparison of participants perception of the visual changes in the signs of skin aging as a result of using the test product compared to the control product. [Baseline to Day 60]

    Time frame: 60 days

    Measured via participant-reported questionnaires. Questionnaires will be designed using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). The left side of the face and the right side of the face will be compared.

Sponsors and collaborators

Lead sponsor

Dime Beauty Co.

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Nov 9, 2023
Registry last updated
Feb 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.